New drug VedAryo® shows promise for IBD patients in Real-World study

NCT ID NCT07273760

First seen Jan 06, 2026 · Last updated May 01, 2026 · Updated 25 times

Summary

This study followed 150 people with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who were treated with VedAryo® (vedolizumab). The goal was to see if the drug helps control symptoms and is safe over 52 weeks. Researchers measured improvements in disease activity scores and tracked any side effects. The study did not compare VedAryo® to any other treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dr. Ali Beheshti-Namdar Clinic

    Mashhad, Razavi Khorasan Province, Iran

  • Dr. Hamid Asadzadeh Aghdaei Clinic

    Tehran, Iran

  • Dr. Hassan Vossoughinia Clinic

    Mashhad, Razavi Khorasan Province, Iran

  • Dr. Mahtab Shabani Clinic

    Tehran, Iran

  • Dr. Mohammad-Javad Kaviani Clinic

    Shiraz, Fars, Iran

  • Dr. Naser Ebrahimi Daryani Clinic

    Tehran, Iran

  • Gilan Gastroenterology and Hepatology Subspecialty Clinic

    Rasht, Gilan Province, Iran

  • Imam Khomeini Hospital

    Tehran, Iran

  • Mehr Specialty Clinic

    Tehran, Iran

  • Professor Shahram Agah Gastroenterology, Hepatology, and Endoscopy Subspecialty Clinic

    Tehran, Iran

  • Shariati Hospital

    Tehran, Iran

  • Taleghani Hospital

    Tehran, Iran

Conditions

Explore the condition pages connected to this study.